Adverse Reactions, Including Death, Associated with Cypher Heart Stent

Kahn Gauthier Swick are investigating any possible lawsuit against Cordis Corporation on behalf of persons who have been injured by the Cordis's Cypher sirolimus eluting coronary stent. On October 29, 2003, the federal Food and Drug Administration issued a warning that a significant number of adverse effects had been reported since the Cypher sirolimus eluting coronary stent was approved on April 24. Both blood clotting and hypersensitivity reactions have been reported.

The Cypher sirolimus eluting coronary stent was approved for patients undergoing angioplasty procedures to open clogged coronary arteries. The Cypher sirolimus eluting coronary stent, a cylindrical metal mesh, is designed to keep the arteries from re-clogging after the procedure. The Cypher sirolimus eluting coronary stent is coated with a thin polymer containing the drug sirolimus that is slowly released into the patient and is intended to reduce the rate of re-blockage that occurs with other stents.

As of October 10, 2003, Cordis, a Johnson & Johnson company, reports that more than 450,000 Cypher sirolimus eluting coronary stents have been distributed worldwide, with more than 260,000 of these Cypher sirolimus eluting coronary stents in the U.S. The FDA does not have enough information to determine whether the incidents of thrombosis and hypersensitivity reaction with the Cypher sirolimus eluting coronary stent differ from those experienced with bare metal stents.

File a claim today for a cypher stent lawsuit.